Navigation Links
Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial
Date:6/16/2008

e assessment of the potential relationship between germline and/or tumor DNA sequence alterations and the efficacy of XL184, as well as assessment of pharmacodynamics and pharmacokinetics of XL184. It is expected that approximately 100 sites in 20 countries will participate in this study.

"We are very encouraged by the level of clinical activity in the ongoing XL184 phase 1 study showing a high response rate and durable disease control in medullary thyroid cancer patients, and believe that the FDA-approved phase 3 study design will allow us to rigorously evaluate the clinical benefit of XL184 in this population for which no standard of care is available," said Gisela Schwab, MD, executive vice president and chief medical officer at Exelixis.

The planned initiation of this phase 3 trial is based on encouraging data that were presented earlier this month at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO). Safety and clinical activity data were presented from an ongoing phase 1 trial of XL184 in 69 patients with various solid tumors, including 17 response-evaluable patients with MTC. These data showed a disease control rate (percentage of patients with partial responses or prolonged stable disease >3 months) of 100% in the evaluable MTC patients, with 53% of those patients (9 of 17) experiencing partial responses. The median duration of partial responses and stable disease for patients with MTC has not been reached (range 1+ to 22+ months). Most of the MTC patients in the trial had previously failed other treatments, including tyrosine kinase inhibitors with anti-RET activity (e.g., vandetanib, sorafenib, or motesanib), chemotherapeutic agents, immunotherapy, radioactive iodine, and radiotherapy.

Several additional studies with XL184 have recently been initiated to complement the planned pivotal trial in patients with MTC as part of Exelixis' strategy to rapidly advance compounds into areas of high unmet medical need whi
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
2. Exelixis Receives $150 Million Funding Commitment From Deerfield Management
3. Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
4. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
5. REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
6. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
7. Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference
8. Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
9. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
11. Option to Develop Exelixis Compound Exercised By Genentech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015 E-QURE Corp. (OTCQB: EQUR), ... Bio-electrical Signal Therapy device ("BST Device"), a new and ... heal chronic wounds, today announced that the Company has ... distributor specializing in medical devices, for the marketing and ... a 70 years old, sales, marketing and distribution company ...
(Date:8/3/2015)... , Aug. 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... focused on the development of autologous cell therapies, announced today ... at the InvestMNT conference held in Minneapolis, Minnesota ... local time. Hall,s presentation will highlight RepliCel,s 18-month milestones including ... Europe , clinical data from both RCT-01 ...
(Date:7/31/2015)... ... 2015 , ... Global Resorcinol Market 2015-2019 is a comprehensive ... global resorcinol industry. The report highlights the various growth prospects and the prevalent ... of primary and secondary inputs from the existing players of the resorcinol market. ...
(Date:7/30/2015)... Marshall, MN (PRWEB) , ... July 31, 2015 , ... ... Ralco Enrichment Center at the Lyon County Fair to be held August 5-9 in ... more about where their meals come from and how agriculture impacts their daily lives. ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
... In its third year as a contestent, Vector Surgical ... to improve breast cancer surgery, is the winner of the ... the winner in the life sciences category, beat out three ... the Wisconsin Entrepreneurs' Conference . The 2007 contest, produced ...
... Matt Storms is writing a series of articles on raising ... on managing the offering process after the Private Placement Memorandum ... , ,Here's a conversation overheard at a recent conference: , ... investors since showing up two hours ago. Each of ...
... member of Congress announces that a major reason to reform the ... does it like us. , ,Even during an era when America-bashing ... well - and has always done well - much to the ... things is innovation. In fact, the United States is the greatest ...
Cached Biology Technology:Surgical products company wins Governor's Business Plan Contest 2Surgical products company wins Governor's Business Plan Contest 3Surgical products company wins Governor's Business Plan Contest 4In pursuit of capital, be sure to track your private offering 2In pursuit of capital, be sure to track your private offering 3In pursuit of capital, be sure to track your private offering 4In pursuit of capital, be sure to track your private offering 5In pursuit of capital, be sure to track your private offering 6Changes to U.S. patent law must nurture our culture of innovation 2Changes to U.S. patent law must nurture our culture of innovation 3Changes to U.S. patent law must nurture our culture of innovation 4
(Date:7/31/2015)... julio de 2015 La 10 th International ... medio de BGI del 22 al 25 de octubre de 2015 ... Este año, la conferencia celebra su décimo aniversario. Desde su ... una de las reuniones anuales más influyentes del mundo en ... más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Huawei has selected ... solution for its stylish smartwatch. Huawei chose the ... reliability, low power and highly responsive human interface ... Huawei designers also required a classic round watch ...
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... chromosomes, which are normally bar-shaped, instead bend into a ... cause a multitude of problems. Genetics experts at The ... disorder, supported by a $126,000 grant from the Ring ... because it affects the 20th of the 23 human ...
... National Human Genome Research Institute (NHGRI), part of the ... more than $80 million over the next four years ... which in its pilot phase yielded provocative new insights ... Based on ENCODEs early success, we are moving ...
... Springer, one of the leading global STM publishers, has ... (ERF) for the journal Estuaries and Coasts. Appearing ... role in promoting research on and management of estuarine ... Springer will be February 2008. The partnership will ...
Cached Biology News:Grant supports study of abnormal ring-shaped chromosomes 2Researchers expand efforts to explore functional landscape of the human genome 2Researchers expand efforts to explore functional landscape of the human genome 3Researchers expand efforts to explore functional landscape of the human genome 4Researchers expand efforts to explore functional landscape of the human genome 5Researchers expand efforts to explore functional landscape of the human genome 6Estuarine Research Federation chooses Springer as publishing partner 2
Request Info...
Mouse Aminopeptidase P2/XPNPEP2 Biotinylated Aff Pur PAb Keywords: AminopeptidaseP2, Metalloproteinase, Metalloprotease, X-Prolyl Aminopeptidase 2, X-Pro Aminopeptidase 2, Membrane-bound Prote...
Request Info...
AGAROSE PREP, 50G, 1 EA. Category: Genephor Precast Gels....
Biology Products: